December 5, 2015 12:01 PM | 1 min read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Atara Biotherapeutics, Inc. (Nasdaq: ATRA) today announced that its collaborating investigators at Memorial Sloan Kettering Cancer Center (MSK) are reporting positive Phase 1 clinical data for Atara's WT1-CTL product candidate during the 2015 ASH Annual Meeting. The findings describe the safety and activity of primary donor-derived WT1-CTLs following allogeneic hematopoietic cell transplantation (alloHCT) for the treatment of patients with relapsed-refractory multiple myeloma (MM), including plasma cell leukemia (PCL). Dr. Guenther Koehne, M.D. and colleagues are reporting positive clinical data from the ongoing Phase 1 trial: 7 patients with relapsed-refractory MM, including PCL were treated with alloHCT followed by WT1-CTLs.By one year, 3 achieved a complete remission (CR), 1 achieved a partial response (PR), 2 had stable disease (SD), and 1 had progressive disease.2 patients who developed a CR remain in remission for more than 1 year.There were no
See full press release
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.